Ontario Court of Appeal: Apotex not entitled to damages for generic drug's delayed market entry
The Ontario Court of Appeal has ruled that generic drugmaker Apotex is not entitled to damages for the delayed entry of a generic drug that was based on a patent held...To view the full article, register now.
Already a subscriber? Click here to view full article